Pulmonary Arterial Hypertension Market Size, Share & Trends Report

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-2-68038-855-8
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the pulmonary arterial hypertension market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for pulmonary arterial hypertension market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of pulmonary arterial hypertension market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Pulmonary Arterial Hypertension Market Categorization:

The pulmonary arterial hypertension market was categorized into four segments, namely drug class (Endothelin Receptor Antagonists, PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), type (Branded, Generics), route of administration (Oral, Intravenous/ subcutaneous, Inhalational), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

Segment Market Methodology:

The pulmonary arterial hypertension market was segmented into drug class, type, route of administration, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The pulmonary arterial hypertension market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; the UK; Germany; Italy; France; Spain; Sweden; Denmark; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Pulmonary arterial hypertension market companies & financials:

The pulmonary arterial hypertension market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • JOHNSON & JOHNSON SERVICES, INC. - Johnson & Johnson is a holding company that is involved in R&D, manufacturing, and sales of healthcare products. It operates through three reportable segments: Pharmaceuticals, Medical Devices, and Consumers. The pharmaceuticals segment focuses on infectious diseases & vaccines, immunology, neuroscience, cardiovascular, oncology, and pulmonary hypertension. The medical devices segment offers devices used in cardiovascular, orthopedic, diabetes care, surgery, and eye health fields. The consumer segment comprises oral care, baby care, beauty, women’s health, over-the-counter pharmaceuticals, and wound care. The company has an established line of pulmonary arterial hypertension treatment, owing to when it acquired the pulmonary arterial hypertension treatment line from Actelion Pharmaceuticals, Ltd. in June 2017.

  • GILEAD SCIENCES, INC. - Gilead Sciences, Inc. is a research-based biopharmaceutical company that caters to several life-threatening diseases such as liver diseases, HIV, cancer, inflammatory & respiratory disorders, and cardiovascular conditions. Atripla, Emtriva, Tybost, Travuda, Hepsera, Zydelig, Lexiscan, Ranexa, Tamiflu, Macugen, and Letairis are some of the key brands of the company. It has operations in North America, Europe, and Australia. The company’s cardiovascular programs and developments are managed from Fremont, California. It has manufacturing and R&D facilities across five states in the U.S.

  • UNITED THERAPEUTICS CORPORATION - United Therapeutics Corporation is a biotechnology company that develops, manufactures, and distributes innovative medications for chronic & life-threatening diseases. The product portfolio of the company includes pulmonary arterial hypertension and anticancer agents. It provides prostacyclin analogs and PDE-5 inhibitors, which are pulmonary arterial hypertension agents. The company is constantly innovating solutions to serve cardiovascular, pulmonary, cancer, and other orphan diseases. The company has additional facilities in North Carolina, Canada, Chertsey, Surrey, and the UK.

  • ACCELERON PHARMA, INC. - Acceleron Pharma, Inc. is dedicated to drug discovery, development, and marketing of therapeutics to treat rare & serious diseases. The company focuses its R&D efforts on pulmonary diseases, neuromuscular, and hematologic. The company collaborated with Celgene to develop a treatment for chronic anemia in myelodysplastic syndromes, myelofibrosis, and beta-thalassemia. The company is growing its reach in the pulmonary arterial hypertension market with its new approved drug, Sotatercept.

  • GLAXOSMITHKLINE PLC (GSK) - GlaxoSmithKline plc (GSK) is a healthcare company that develops, manufactures, and markets medicines, vaccines, & consumer healthcare products. In 2000, Glaxo Wellcome plc and SmithKline Beecham merged to form GSK. As of 2018, it had a presence in nearly 115 countries. The pharmaceutical segment of the company provides solutions for respiratory, oncology, immune-inflammation, and HIV. Moreover, the company has 86 manufacturing facilities across 36 countries.

  • PFIZER, INC. - Pfizer, Inc. is involved in the R&D and manufacturing of pharmaceutical products. It translates advanced science & technologies into efficient treatment regimens. The company focuses on major therapeutic areas such as cardiovascular diseases, vaccines, oncology, neurosciences, immunology, and rare diseases. Pfizer's R&D activities are categorized as BioTherapeutics R&D Group-involved in large-molecule research-and PharmaTherapeutics R&D Group-focused on small-molecules & related modalities discovery. The company is also engaged in investigator-initiated research and compound transfer programs for third-party agents to conduct studies.

  • BAYER AG - Bayer AG is a pharmaceutical and research-based company that is involved in research, manufacturing, and marketing of animal & human healthcare and medical products. The company operates through four main divisions: animal health, medical care, pharmaceuticals, and consumer care. Its consumer care division focuses on nonprescription medicines, dietary supplements, and dermatology products. The medical care division comprises blood glucose meters, diagnostic imaging agents, and mechanical systems for the treatment of constricted vessels. The company’s pharmaceuticals division focuses on prescription medicines for conditions related to the heart, infectious diseases, and others.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Pulmonary Arterial Hypertension Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 to 2023, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Pulmonary Arterial Hypertension Market Report Assumptions:

  • The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon